To synthesize, integrate, and comment on recent research developments to our understanding of the molecular basis of ependymoma (EPN), and to place this in context with current treatment and research efforts.
INTRODUCTION
Ependymoma (EPN) is a histologically defined tumor of the central nervous system that occurs in children and adults. EPNs of childhood arise most commonly within the supratentorial brain (ST i.e., cerebral hemispheres) or posterior fossa (PF, i.e., cerebellum and brainstem). Spinal EPNs occur most often in adulthood. Treatment for EPN to this date remains maximal-safe surgical resection followed by conformal radiation [1] . The effectiveness of chemotherapy for treatment of EPN is still highly debated and continues to be evaluated in numerous ongoing clinical trials (United States -ACNS0831, Europe -SIOP EPN II). There are no targeted therapies in clinical use or being evaluated in multicenter clinical trials for EPN. As a result, survival rates have seen limited improvement (80%) in the last decade, with survivors suffering from the debilitating side effects of treatment-related surgery and radiation.
Historically, histopathologic features have been used to diagnose and risk-stratify EPN. However, there has been a failure to develop consistent and reliable criteria to predict EPN patient survival, outside of WHO Grade I tumors (i.e., subependymoma myxopapillary EPN) [2] . Frustration with a lack of consistency with respect to EPN histopathologic grading has motivated clinicians and researchers to leverage unbiased, sensitive, and molecular approaches to both develop reliable prognostic markers of EPN, and to decipher the molecular biology of this disease to identify the first set of targeted therapies [3,4,5 && ,6-8,9 && ]. The current review provides a synthesis of recent molecular research developments in the field of EPN. We describe the integration and impact of molecular tools and knowledge on our understanding of the biology of EPN. We comment upon how these findings may be interpreted with respect to clinical treatment and variables, and propose research areas that require potential future investment.
Through independent analysis of multiple EPN cohorts, using transcriptomics, genomics, and epigenomics (termed '-omics') technologies, we now recognize that EPNs are divided into multiple clinically and biologically distinct subgroups. The most recent large-scale analysis reveals that EPNs are segregated into at least nine molecular subgroups (Fig. 1) . PF EPNs are divided into frequent PF-EPN-A tumors (74% of PF EPNs) with a poor outcome, and relatively balanced genome, versus PF-EPN-B tumors with increased genomic instability and a favorable outcome [7, 8, 11] (Fig. 1 
Clinical integration of ependymoma subgroups
Molecular profiling of multiple large EPN cohorts (namely, through Illumina DNA methylation analysis) has allowed for analyses to be made on the impact of molecular subgroup and clinical variables [5 && ,9 && ,11]. A study of four distinct PF EPN cohorts revealed that although using radiotherapy is effective in the case of PF-EPN-A tumors that were grosstotally resected, it had limited impact in patients harboring PF-EPN-A EPN with a subtotal resection [5 && ]. In the same vein, current clinical trial cohorts that are addressing important questions related to other modalities such as the role of chemotherapy (United States -ACNS0831) need to be analyzed in the context of molecular subgroup. In the case of PF-EPN-B, there potentially exists a population of patients that may be cured with surgery alone and, in the case of recurrence, may be salvaged with radiotherapy [5 && ]. This raises a possibility of future clinical efforts to study therapy de-escalation for PF-EPN-B patients 
Frequent fusion oncoproteins define supratentorial ependymoma
A total of 72% of ST EPNs harbor a gene fusion between C11ORF95 and RELA, now recognized by WHO as a distinct clinical entity [2, 4] . This event leads to sequestration of the C11ORF95-RELA fusion protein within the nucleus causing aberrant Nuclear Factor Kappa B Subunit 1 (NF-kB) activity [4] . Viral overexpression of the C11ORF95-RELA fusion protein in murine embryonic day 14.5 radial glial cells (candidate cell of origin of EPN) is capable of cellular transformation and tumor initiation, when transduced cells are implanted in immunodeficient mice [4] . Although C11ORF95-RELA is the most commonly observed fusion, other fusion events have been observed [4] . Global epigenomic rewiring defines posterior fossa ependymoma.
'-omics'-based tumor characterization will continue to unravel the molecular basis of ependymoma and its subgroups.
reported to have a poor survival, ST-EPN-YAP1 tumors carry a favorable prognosis and respond well to current treatments [9 && ]. There remain several important questions to be validated, that similar to PF EPN, would benefit from an expanded molecular-based analysis of multiple ST EPN cohorts. For example, the incidence of these fusion events in ST EPN needs to be independently validated. Are ST-EPN-YAP1 fused tumors substantially overrepresented from other non-C11ORF95-RELA fusion events? In other cohorts, do YAP1 fused EPNs carry a favorable prognosis? More broadly, do all ST EPNs carry a gene fusion? It will be important that current and future ST EPN clinical trial studies examine the incidence and clinical associations with clinical parameters of oncofusion protein events [10 && ]. Although Illumina DNA methylation provides an indirect (yet highly reliable) measure of molecular subgroup associated with a particular fusion, break apart fluorescence in-situ hybridization can be used to identify and verify samples harboring the C11ORF95-RELA fusion. RNA-seq also provides an approach to identify C11ORF95-RELA fusions and provides a discovery method to identify novel or less obvious fusion events. Therapeutically targeting these fusion oncogenic events is currently a challenge as this class of transcriptional machinery proteins (i.e., transcription factors and regulators) has been challenging in the past to target with small molecules. There may be potential in evaluation of NF-kB or YAP1 inhibitors in preclinical models where available [14, 15] . An important direction moving forward will be to determine if these fusion proteins reveal potential druggable binding partners and synthetic lethal cancer cell dependencies [16,17 & ].
Global epigenomic rewiring defines posterior fossa ependymoma PF EPN is divided into two principle molecular subgroups, PF-EPN-A and PF-EPN-B. PF-EPN-B tumors arise in older children through to adulthood, carry a favorable prognosis, and also demonstrate widespread chromosomal aneuploidy [8] . This is in direct contrast to the most frequent PF-EPN-A subgroup Significantly, diffuse intrinsic pontine gliomas (DIPGs) that carry recurrent K27M mutations exhibit similar patterns of global H3K27me3 and DNA methylation loss, suggesting potentially convergent mechanisms of neoplastic transformation and/or similar cell types or states that give rise to these distinct brain tumor entities [23, 24] . Although very rare, a small subset of PF-EPN-A EPNs harbor K27M mutations, raising the question as to what is the cause of global DNA and H3K27me3 loss in nonhistonemutated EPN [25] . This also raises the opportunity for potential shared therapeutic paradigms to exploit dysregulated epigenomes. As seen in EPN and DIPG, the residual H3K27me3 in tumors is important for tumor cell maintenance, because inhibition with EZH2 inhibitors is sufficient to block tumor cell growth [11, [18] [19] [20] 26] . Research efforts in the future may benefit from exploring the potential for exploiting tumors that demonstrate global H3K27me3 loss for potential synthetic lethal pathways [16,17 & ].
Models desperately needed
Understanding the genetic basis of EPN has led to the development of ex-vivo models through overexpression of the C11ORF95-RELA fusion protein, and implantation of transduced radial glia into immunodeficient mice [3, 4, 6] . This has allowed for the mechanistic dissection of the biology of C11ORF95-RELA fusion protein in initiating and maintaining EPN tumorigenesis in mouse models. These mouse isogeneic models offer opportunities to identify ST-EPN-RELA cell dependencies through mechanistic study, and genetic and chemical screens. They also provide a foundation for development of transgenic EPN models, which would be useful for mapping the cellular origins of the disease. Still widely lacking is the availability of human patient derived models. In the case of C11ORF95-RELA tumors, the model EP1-NS harbors the RELA fusion and shares similar transcriptional and DNA methylation signatures with human primary ST-EPN-RELA tumors (data unpublished) [27] . Given the number of EPN subgroups, additional models are desperately needed for preclinical therapeutic development. This is especially the case for PF-EPN-A EPN in which primary cultures can be maintained for a few passages before they senescence or begin to exhibit patterns of genetic and epigenetic drift. Given the rarity of these tumors, collaborative efforts are essential to establishing, sharing, and characterizing new EPN models in order for biological advancements to proceed [10 && ].
Conclusion: the future of '-omics' to study ependymoma '-omics'-based discovery approaches identified the main driver of ST EPN. Can additional applications such as epigenomics, proteomics, single cell analysis, and metabolomics reveal other oncogenic drivers, and offer further insight into the mechanisms of EPN-genesis? Such analysis may proof useful in the case of PF-EPN-A and PF-EPN-B EPNs in which frequent drivers are unknown. For example, the repressive landscape has been defined through histone methylation mapping, but what about other epigenetic modifications in particular active epigenomic marks, such as H3K27 acetylation? Could these actively transcribed domains reveal recurrent regulatory programs that lead to oncogenic activation as reported in other brain tumors? [28] Will metabolic approaches performed in primary tumors help us determine the optimal conditions for primary cell culture, such that more models are established, and platforms can be developed for therapeutic screening? Have we missed cryptic lesions or mutations that might be revealed with advanced genomic sequencing? Have we underestimated the full degree of heterogeneity within subgroups of EPN, and that these tumors -like medulloblastoma -are composed of many more subtypes [29, 30] . These questions may be answered readily with continued partnerships between researchers and clinicians, working toward international collaboration and shared access to samples, models, and data.
